HSBC Holdings’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

HSBC Holdings’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-783,092	Closed	-$46M	–	3294
2023 Q4	$46M	Buy	+783,092	New	+$44M	0.04%	438
2023 Q1	–	Sell	-23,469	Closed	-$1.03M	–	3169
2022 Q4	$1.03M	Buy	+23,469	New	+$1.52M	﹤0.01%	1957
2022 Q3	–	Sell	-23,998	Closed	-$1.61M	–	3346
2022 Q2	$1.61M	Buy	23,998 +16,721	+230%	+$1.06M	﹤0.01%	1692
2022 Q1	$609K	Buy	+7,277	New	+$744K	﹤0.01%	2270
2021 Q3	–	Sell	-3,828	Closed	-$623K	–	3209
2021 Q2	$623K	Buy	+3,828	New	+$615K	﹤0.01%	2035
2021 Q1	–	Sell	-8,658	Closed	-$1.91M	–	3217
2020 Q4	$1.91M	Buy	+8,658	New	+$1.87M	﹤0.01%	1354
2020 Q3	–	Sell	-4,229	Closed	-$483K	–	2906
2020 Q2	$483K	Buy	+4,229	New	+$410K	﹤0.01%	1858

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HSBC Holdings's MRTX Position: Q1 2024 in Review

HSBC Holdings sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 783,092 shares — an estimated $46M sold.

HSBC Holdings first reported a position in MRTX in Q2 2020 and held it in 7 quarters. The position peaked at $46M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

HSBC Holdings reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
HSBC Holdings sold 783,092 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $46M.
HSBC Holdings first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2020 and held it in 7 quarters.
HSBC Holdings's Mirati Therapeutics, Inc. Common Stock position peaked at $46M in Q4 2023.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on HSBC Holdings's 13F filing for Q1 2024, filed 15 May 2024.